Page last updated: 2024-11-01

ofloxacin and Macular Holes

ofloxacin has been researched along with Macular Holes in 2 studies

Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

Research Excerpts

ExcerptRelevanceReference
"Equal dosing with topical administration of levofloxacin 0."2.72Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye. ( Lokkila, J; Nurmenniemi, P; Puustjärvi, T; Teräsvirta, M; Uusitalo, H, 2006)
"Levofloxacin was detectable 2."2.70Vitreous penetration of levofloxacin in the uninflamed phakic human eye. ( Groenewald, C; Herbert, EN; McGalliard, J; Pearce, IA; Wong, D, 2002)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Puustjärvi, T1
Teräsvirta, M1
Nurmenniemi, P1
Lokkila, J1
Uusitalo, H1
Herbert, EN1
Pearce, IA1
McGalliard, J1
Wong, D1
Groenewald, C1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Clinical Safety of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%[NCT04212429]Phase 1/Phase 2128 participants (Anticipated)Interventional2019-09-23Recruiting
The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%[NCT04214821]Phase 1/Phase 2128 participants (Anticipated)Interventional2019-09-23Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

2 trials available for ofloxacin and Macular Holes

ArticleYear
Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2006, Volume: 244, Issue:12

    Topics: Administration, Topical; Aged; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Double-B

2006
Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2006, Volume: 244, Issue:12

    Topics: Administration, Topical; Aged; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Double-B

2006
Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2006, Volume: 244, Issue:12

    Topics: Administration, Topical; Aged; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Double-B

2006
Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2006, Volume: 244, Issue:12

    Topics: Administration, Topical; Aged; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Double-B

2006
Vitreous penetration of levofloxacin in the uninflamed phakic human eye.
    The British journal of ophthalmology, 2002, Volume: 86, Issue:4

    Topics: Administration, Oral; Aged; Anti-Infective Agents; Female; Humans; Levofloxacin; Male; Middle Aged;

2002